Semaglutide Trial Initiated for New-Onset Idiopathic Intracranial Hypertension, Comparing to Standard Weight Management

Idiopathic Intracranial Hypertension (IIH) is a condition characterized by elevated intracranial pressure without an identifiable cause, strongly associated with obesity. Current management often involves weight loss, but the efficacy of specific pharmacological interventions like GLP-1 receptor agonists (GLP-1RAs) compared to standard weight management strategies remains underexplored. This trial aims to address the need for comparative evidence in new-onset IIH, potentially offering a targeted therapeutic approach beyond conventional weight loss methods.

This randomized controlled trial will enroll 50 patients with verified new-onset Idiopathic Intracranial Hypertension. Participants are randomly allocated to either standard weight management via dietician counseling or a trial intervention. The intervention arm receives Semaglutide via subcutaneous injections for 10 months, combined with an initial 8-week Very Low Calorie-Diet (max 800 kcal/day). Primary endpoints include changes in weight and intracranial pressure, comparing the two approaches.

This record describes a clinical trial design, and as such, no results or findings are available yet. The study is designed to compare the efficacy of Semaglutide with standard weight management in patients with new-onset Idiopathic Intracranial Hypertension, with primary outcomes focused on changes in weight and intracranial pressure. Data collection and analysis are pending the completion of the trial.